M
Maartje I. Kester
Researcher at VU University Medical Center
Publications - 21
Citations - 1219
Maartje I. Kester is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Apolipoprotein E & Cognitive decline. The author has an hindex of 16, co-authored 21 publications receiving 1053 citations.
Papers
More filters
Journal ArticleDOI
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Maartje I. Kester,Charlotte E. Teunissen,Daniel L. Crimmins,Elizabeth M. Herries,Jack H. Ladenson,Philip Scheltens,Wiesje M. van der Flier,John C. Morris,David M. Holtzman,Anne M. Fagan +9 more
TL;DR: Neurogranin is a promising biomarker for AD because levels were elevated in patients with AD compared with cognitively normal participants and predicted progression from MCI to AD, and within-person levels of NGRN increased in cognitivelynormal participants but not in Patients with later stage MCI or AD, which suggests that N GRN may reflect presymptomatic synaptic dysfunction or loss.
Journal ArticleDOI
Patients With Alzheimer Disease With Multiple Microbleeds Relation With Cerebrospinal Fluid Biomarkers and Cognition
Jeroen D. C. Goos,Maartje I. Kester,Frederik Barkhof,Martin Klein,Marinus A. Blankenstein,Philip Scheltens,Wiesje M. van der Flier +6 more
TL;DR: Microbleeds are associated with the clinical manifestation and biochemical hallmarks of Alzheimer disease, suggesting possible involvement of MBs in the pathogenesis of Alzheimer Disease.
Journal ArticleDOI
Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers
Maartje I. Kester,Jeroen D. C. Goos,Charlotte E. Teunissen,Marije R. Benedictus,Femke H. Bouwman,Mike P. Wattjes,Frederik Barkhof,Philip Scheltens,Wiesje M. van der Flier +8 more
TL;DR: Deposition of amyloid appears aggravated in patients with cerebral small-vessel disease, especially in apolipoprotein E ε4 carriers, providing evidence for pathophysiological synergy between these 3 biological factors.
Journal ArticleDOI
CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Maartje I. Kester,A. E. van der Vlies,Marinus A. Blankenstein,Y.A.L. Pijnenburg,E. J. van Elk,Philip Scheltens,W.M. van der Flier +6 more
TL;DR: It is hypothesized that high tau, especially in combination with relatively low p-tau-181, is a marker of rapid decline, since it has been associated with fast neuronal degeneration in patients with AD.
Journal ArticleDOI
Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort
Maartje I. Kester,Charlotte E. Teunissen,Courtney L. Sutphen,Elizabeth M. Herries,Jack H. Ladenson,Chengjie Xiong,Philip Scheltens,Wiesje M. van der Flier,John C. Morris,David M. Holtzman,Anne M. Fagan +10 more
TL;DR: CSF levels of YKL-40 may have utility for discriminating between cognitively normal individuals and patients with MCI or AD and increased levels of both YKl-40 and VILIP-1 may be associated with disease progression.